Stay updated with breaking news from Ben Matone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in... | November 10, 2022
/PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious...
GuruFocus Article or News written by PRNewswire and the topic is about:
/PRNewswire/ -- INOVIO (NASDAQ: INO) announced results from the company's novel Phase 1/2 trial of INO-5401 and INO-9012 in combination with PD-1 inhibitor...
Announces prioritization of heterologous booster strategy for COVID-19 vaccine candidate INO-4800 and discontinuation of Phase 3 INNOVATE trial to optimize...